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Cytochrome P450 genetic polymorphisms are responsible for individual variations in drug metabolism and drug-drug 
interactions. They are very important for pharmacogenetics, and their frequency varies across different populations. There 
is a big gap in the knowledge about the CYP gene family polymorphisms in the population of Kosovo, and the aim of 
our study was to fill that gap by determining the frequency of the most important variant alleles of CYP2C9, CYP2C19, 
and CYP3A5 in 234 nonrelated Kosovars. The allele frequencies of CYP2C9*2 and 2C9*3 were 17.52 %, and 10.89 %, 
respectively. Sixteen participants (6.81 %) were CYP2C9 poor metabolisers. The CYP2C19*2 and *17 variant frequencies 
were 13.03 % and 19.01 %, respectively. There were 2.13 % CYP2C19 poor and 4.27 % ultra-rapid metabolisers 
(homozygous carriers of the *17 allele). With regard to CYP3A5, the frequency of the *3 variant allele was 98.29 % 
(non-expressors), while the remaining participants (1.70 %) were expressors of CYP3A5. These findings are comparable 
with other European ethnicities, specifically those of Southeast Europe.
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Individual variability in response to the most common 
drugs presents one of the major challenges to 
pharmacotherapy today. This variability depends on a 
variety of factors (drug interactions, hepatorenal disorders, 
sex, age, and lifestyle), but the most challenging are the 
genetic polymorphisms that have a direct and important 
impact on drug-detoxifying enzymes, drug targets, and drug 
transporters (1-3). Phase I enzymes metabolise nearly 59 % 
of the drugs reported for adverse drug reactions (ADR), 
and cytochromes P450 (CYP450 or CYP) make 75–86 % 
of these phase I enzymes (2, 4). Their genetic variants are 
responsible for unintended drug metabolism and interactions 
(5) that can lead to toxicity or failed pharmacotherapy (6). 
This has been recognised by the US Food and Drug 
Administration (FDA) and European Medicines Agency 
(EMA), as both push policies requiring that pharmacogenetic 
information is provided for drug development and 
postmarketing surveillance (7, 8).
The most important genetic variants of CYP in clinical 
practice include those of CYP2C9, CYP2C19, and CYP3A5. 
Their frequencies vary across populations, and mapping 
them, so to speak, can be very useful in designing specific 
pharmacotherapy. To the best of our knowledge no such 
mapping has been done for the population of Kosovo, a 
southeast European country of over 1.7 million people, 
93 % of whom are ethnic Albanians. The aim of our study 
was to address this gap and determine the frequency of the 
pharmacologically most important variant alleles of 
CYP2C9, CYP2C19, and CYP3A5 in Kosovo population, 
hoping that our findings could help to optimise 
pharmacotherapy in the country.
PARTICIPANTS AND METHODS
This study included a mixed population of 234 randomly 
selected Caucasians (116 women and 118 men) with no 
blood relation from all parts of Kosovo. Their age ranged 
between 18 and 65 years (median: 36 years). The main 
exclusion criteria were mental illnesses or a history of 
serious physical illness.
The study was approved by the Ethics Committee of 
the University Clinical Centre of Kosovo in Prishtina 
(Kosovo) and by the Faculty of Pharmacy in Skopje 
(Macedonia), where genotyping was performed. Prior to 
enrolment, all participants gave their written consent for 
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participation. The study was performed according to the 
principles expressed in the Declaration of Helsinki.
We determined the frequencies of the most common 
variant alleles of polymorphic CYP enzymes: CYP2C9*2 
(c.430C>T, rs1799853), CYP2C9*3 (c.1075A>C, 
rs1057910), CYP2C19*2 (c.681G>A, rs4244285), 
CYP2C19*17 (c. 806C>T, rs12248560), and CYP3A5*3 
(g.6986A>G, rs776746). The CYP2C19*3 (c.636G>A, 
rs57081121) allele was excluded as very rare in the 
European population (9, 10).
For genotyping we collected 5 mL of peripheral blood 
from each subject into test tubes with the anticoagulant 
ethylene diamine tetra-acetic acid (EDTA). Genomic DNA 
was extracted from whole blood using a QIAGEN DNA 
extraction kit (QIAGEN AS, Oslo, Norway). The extracted 
DNA concentrations were determined with a NanoDrop 
2000TM spectrophotometer (Thermo Fisher Scientific, 
Wilmington, DE, USA).
CYP2C9*2  (C_25625805_10) ,  CYP2C9*3 
(C_27104892_10), CYP2C19*2 (C_25986767_70), 
CYP2C19*17  (C_469857_10) ,  and CYP3A5*3 
(C_26201809_30) were genotyped using a TaqMan® drug 
metabolism genotyping assay or a TaqMan® single 
nucleotide polymorphism (SNP) genotyping assay (Applied 
Biosystems, Foster City, CA, USA) on an Mx3005P real-
time quantitative polymerase chain reaction (QPCR) system 
with pertaining MxPro software ) (Agilent Technologies, 
Santa Clara, CA, USA) following the manufacturer’s 
instructions.
In order to multiply a DNA segment, we mixed 2 µL of 
DNA with 10.5 µL of PCR and incubated the mixture under 
the following conditions: uracil-N-glycosylase incubation 
(2 min at 50 °C), AmpliTaq Gold® activation (10 min at 
95 °C), PCR [50 cycles: denaturation (15 sec at 92 °C); 
annealing/extension (60 sec at 60 °C)].
Statistical analysis
The variables were analysed with an SPSS statistical 
program (SPSS Inc., Chicago, IL, USA, 20.0 version) and 
online calculator (available at https://www.allto.co.uk/tools/
statistic-calculators/confidence-interval-for-proportions-
calculator). Allele and genotype frequencies were estimated 
using the gene counting method, and their distribution was 
tested with the chi-squared test for the Hardy-Weinberg 
equilibrium.
Using the chi-squared test with Yate’s correction we 
compared our allele frequency distribution with other 
studies to establish differences or similarities with other 
populations, Caucasian in particular. The threshold of 
significance was set at a 5 %, where all differences above 
p=0.05 were considered non-significant between our results 
and the reported frequencies in other populations.
RESULTS AND DISCUSSION
Our findings of the CYP gene polymorphisms in the 
Kosovar sample are similar to other European populations 
reported in several publications (11–13). Tables 1–3 show 
genotype distribution and the predicted phenotypes of 
CYP2C9, CYP2C19, and CYP3A5. All genotype frequencies 
were in line with the Hardy-Weinberg principle.
CYP2C9
The CYP2C9 allele frequencies compare to other 
European Caucasians, such as Croats (Southeast Europe) 
and the French (West Europe) (14, 15). The CYP *2 and *3 
allele frequencies in our sample were 17.52 % and 10.89 %, 
respectively. The frequency of CYP2C9 poor metabolisers 
was 6.8 %, which is similar to the Spanish (5.0 %) (16) and 
Macedonian (5.1 %) population, but differs from England’s 
population (3.2 %) (17, 18). The following frequencies of 
CYP2C9*2 have been reported for the European 
Mediterranean and other European countries: Spain 
(16.0 %), Greece (12.9 %), Croatia (14.0 %), Romania 
(11.3 %), Germany (14.0 %), France (15.0 %), and Sweden 
(10.7 %) (19–25). CYP2C9*3 has the highest prevalence 
in Southern Asian populations (10.1 %) (25), while in the 
Western, Central, and Southeastern Europe it is present in 














No. of alleles 
(2n) / (%)
CYP2C9*1/*1 117 50.00 43.59 - 56.41 EM CYP2C9*1 335  (71.58)
CYP2C9*1/*2 62 26.49 20.84 - 32.14 IM CYP2C9*2 82  (17.52)
CYP2C9*1/*3 39 16.66 11.89 - 21.43 IM CYP2C9*3 51  (10.89)
CYP2C9*2/*2 8 3.41 1.08 - 5.74 PM
CYP2C9*2/*3 4 1.70 0.04 - 3.36 PM
CYP2C9*3/*3 4 1.70 0.04 - 3.36 PM
PM - poor metabolisers; IM - intermediate metabolisers; EM - extensive metabolisers
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receiving carriers of the CYP2C19*17 allele were reported 
for increased risk of bleeding, the highest risk being for 
those who carried the CYP2C19*17/*17 genotype. Eight 
participants (3.41 %) in our sample were the carriers of the 
CYP2C19*2/*17 combined genotype. Their metabolic 
phenotype is difficult to predict and remains a matter of 
debate. Some data suggest that the presence of the 
CYP2C19*17 allele may not compensate for the inactivating 
effect of CYP2C19*2 (36).
Finally, our results indicate a significant difference from 
other Caucasians, such as Russian (CYP2C19*1/*1; 
p<0.001) (37).
CYP3A5
Over 98.3 % of our participants had the CYP3A5*3/*3 
genotype and are classified as non-expressors. This finding 
corresponds to the other reports for Caucasians (18, 24, 28), 
as it varies from 85 to 96 % (38). The CYP3A5*3 allele 
plays an important role in the pharmacokinetics of 
tacrolimus (basic therapy for immunosuppression in patients 
who undergo solid organ and haematopoietic stem cell 
transplantation) and imatinib (a tyrosine kinase inhibitor, 
which is the drug of choice in treating blood malignancies 
such as chronic myeloid leukaemia) (39). Statistical analysis 
showed a significant similarity with Croats (95.5 %; 
p=0.072), Basques (96.0 %; p=0.143), and Poles (96.3 %; 
p=0.180) (16, 24, 40).
CONCLUSION
Even though our study is limited to the most important 
CYP alleles (SNPs) and a relatively small sample, it clearly 
the following frequencies: France 8.0 %, Belgium 7.4 %, 
Hungary 8.8 %, Croatia 9.5 %, Greece 8.1 %, and 
Macedonia 7.3 % (14, 15, 23, 26–28)..
CYP2C19
Genotyping the CYP2C19 alleles in Kosovars revealed 
the *2 and *17 allele frequencies of 13.03 % and 19.01 %, 
respectively, which are comparable to other Caucasians. 
CYP2C19*2 is the most common variant allele in 
Caucasians, and its frequency varies from 13.1 % to 18.7 % 
(23, 29). We found high similarity of our distribution with 
both Macedonia (14.9 %; p=0.55) and Greece (13.1 %; 
p=1.00) (23, 28).
As the CYP2C19*2 is an inactivating allele, knowing 
its distribution in a population is important when prescribing 
medicines such as clopidogrel, which is a pro-drug that 
must be activated by CYP2C19 (30). In this study, five 
participants (2.13 %) were discovered to be homozygous 
carriers of the *2 allele (CYP2C19*2/*2 genotype.
Our findings of the CYP2C19*17 frequency in Kosovars 
are very similar to reports from the neighbouring countries, 
Greece (19.61 %, p=0.69) and Macedonia (20.2 %; p=0.84) 
in particular (23, 24, 31). In Caucasians its frequency varies 
from 15.4 % to 20.2 % (17). The CYP2C19*17 allele was 
documented to be more frequent in the Mediterranean and 
Middle East than in Eastern Asia (32). Even though carriers 
of the CYP2C19*1/*17 and CYP2C19*17/*17 genotype 
were predicted to be ultra-rapid metabolisers, only 
homozygous carriers of the *17/*17 genotype have shown 
a higher rate of metabolism of the CYP2C19 substrates, 
such as tricyclic antidepressants and esomeprazole when 
compared to extensive metabolisers (33-35). Clopidogrel 
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No. of alleles 
(2n) / (%)
CYP2C19*1/*1 107 45.72 39.34 - 52.1 EM CYP2C19*1 318  (67.94)
CYP2C19*1/*2 43 18.37 13.41 - 23.33 IM CYP2C19*2 61  (13.03)
CYP2C19*2/*2 5 2.13 0.28 - 3.98 PM CYP2C19*17 89  (19.01)
CYP2C19*2/*17 8 3.41 1.08 - 5.74 IM
CYP2C19*1/*17 61 26.06 20.44 - 31.68 UM
CYP2C19*17/*17 10 4.27 1.68 - 6.86 UM
PM - poor metabolisers; IM - intermediate metabolisers; EM - extensive metabolisers; UM - ultra-rapid metabolisers
Table 3 CYP3A5 genotype frequencies and predicted phenotype in the Kosovar population sample (N=234)
Genotype No. of participants (N)
Frequency 
(%)
95 % confidence 
interval Predicted phenotype
CYP3A5*1/*1 4 1.7 0.04 - 3.36 expressor
CYP3A5*1/*3 0 0 0 expressor
CYP3A5*3/*3 230 98.3 96.64 - 99.96 non-expressor
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shows a distribution that is consistent with the Caucasian 
ethnicity, especially with the Southeast and Mediterranean 
European populations.
Knowing the distribution of these gene variants in 
Kosovo may prove very useful for the future research of 
certain complex diseases and for determining the impact of 
geographical and climatic conditions in their pathogenesis. 
Our data will form the basis for detecting the genetic risk 
factors related to specific diseases, including the toxic 
potential of numerous environmental pollutants. In addition, 
they can prove relevant to clinical pharmacokinetic studies 
and dosage recommendations for the Kosovo population.
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Genski polimorfizam CYP2C9, CYP2C19 i CYP3A5 u populaciji Kosova
Vrlo visok stupanj polimorfnosti, zbog interindividualne genske varijabilnosti, enzima citokroma P450 (CYP) značajno 
pridonosi raznolikosti u odnosima između primijenjene doze lijeka, koncentracije lijeka u serumu, kao i terapijskoga 
odgovora, ali i interakcije lijekova. Podaci o poznatim polimorfizmima CYP vrlo su važni u kliničkoj primjeni saznanja 
farmakogenetike tj. u samoj farmakoterapiji. Učestalost pojedinih polimorfizama može značajno varirati između različitih 
populacija te je bitno provesti  istraživanja učestalosti u pojedinim populacijama. Do sada nema objavljenih podataka o 
učestalosti polimorfizama gena CYP u populaciji Kosova te je cilj ovog istraživanje bio utvrditi učestalost najvažnijih 
varijanti alela CYP2C9, CYP2C19 i CYP3A5 u toj populaciji. Istraživanje je obuhvatilo 234 stanovnika Kosova koji nisu 
u rodbinskoj vezi. U ispitanika je otkrivena učestalost alela CYP2C9*2  17,52 %, a alela CYP2C9*3 10,89 %, te je 
otkriveno šesnaest ispitanika (6,81 %) sporih metabolizatora CYP2C9. Što se tiče CYP2C19 enzima, učestalost alela 
CYP2C19*2 je 13,03 %, a za alel CYP2C19*17 učestalost je 19,01 %. Uz to, dokumentirano je 2,13 % sporih metabolizatora 
CYP2C19 te 4,27 % homozigotnih nositelja alela *17 (fenotip vrlo brzih metabolizatora). S obzirom na CYP3A5 enzim, 
zabilježena je učestalost alela *3 od 98,29 % (fenotip neekspresora), a 1,70 % ispitanika kategorizirano je kao ekspresori. 
Rezultati istraživanja pokazali su da je varijabilnost alela, genotipova i fenotipova u populaciji Kosova u velikoj mjeri u 
skladu s drugim europskim populacijama, konkretnije s populacijama jugoistočne Europe.
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